LungVision

by BodyVision Medical  · Based in United States → — AI-Powered Lung Cancer Diagnosis and Intervention
Interventional Radiology Oncology Pulmonology

Contact for pricing
Domain VerifiedRegulatory Status Disclosed

Overview

The LungVision® system by BodyVision Medical is an advanced, AI-driven intraoperative imaging and navigation platform designed to revolutionize early lung cancer diagnosis and treatment. It leverages proprietary AI Tomo® technology to transform standard 2D C-arm X-ray images into real-time 3D CT-like scans, providing enhanced visualization and guidance during bronchoscopic procedures.

The system addresses the critical challenge of CT-to-body divergence, which often hinders accurate biopsy of peripheral lung nodules. By fusing preoperative CT data with intraoperative fluoroscopy, LungVision enables real-time augmented endobronchial navigation and offers visual confirmation of the tool-in-lesion, significantly improving diagnostic yield and clinician confidence.

LungVision is designed to be hardware-light and compatible with most existing C-arms, bronchoscopes (including robotic platforms), and biopsy tools, making it an affordable and accessible solution for medical centers. It aims to reduce radiation exposure for both patients and staff compared to traditional 3D imaging systems and streamline procedural workflows.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered real-time 3D imaging from 2D C-arms
  • Multimodal image fusion (preoperative CT & intraoperative fluoroscopy)
  • Augmented endobronchial fluoroscopic navigation and guidance
  • Correction for CT-to-Body Divergence
  • Visual Tool-in-Lesion confirmation
  • Compatibility with standard biopsy instruments, bronchoscopes, and C-arms
  • Reduced radiation exposure compared to 3D C-arms
  • AI-driven suggested lesion location feature
  • Hardware-light, small, and mobile footprint
  • Real-time intraoperative CT scans from X-ray images

Use Cases

  • Peripheral lung nodule biopsy
  • Early lung cancer detection and diagnosis
  • Guidance for endobronchial tools in pulmonary procedures
  • Delivery of localized therapies for lung cancer
  • Enhancing robotic bronchoscopy platforms
  • Minimally invasive lung interventions

What Physicians Need to Know

Key Capabilities
AI-powered software transforms images from any 2D C-arm into real-time 3D images for navigation bronchoscopy. It provides intraoperative imaging for accurate localization and biopsy of small, peripheral lung lesions, correcting for CT-to-body divergence. The system offers augmented fluoroscopy with an overlay of the actual lesion location and enables visual confirmation of tool-in-lesion in multiple 3D planes. It also includes pathway planning and virtual bronchoscopy features.
Clinical Utility
LungVision improves diagnostic yield for peripheral pulmonary nodules, with reported yields approaching 90% and beyond, facilitating earlier-stage lung cancer detection and improved survival rates. It significantly reduces radiation exposure compared to 3D C-arms (e.g., ~1/5 the dose of a Siemens Cios Spin 3D scan) and minimizes procedural duration. The system allows for biopsy of smaller, harder-to-visualize lesions and can facilitate precise delivery of localized therapies, enabling diagnosis and treatment in a single-anesthesia event.
Integration Options
The system seamlessly integrates with existing 2D and 3D C-arms, various navigation platforms (including robotic bronchoscopy systems like Ethicon Monarch and Ion by Intuitive), standard bronchoscopes, and a wide range of endobronchial biopsy tools, such as cryoprobes. It utilizes preoperative CT scans for planning and features a hardware-light design with a small, mobile footprint.
Compliance Status
LungVision has received multiple FDA clearances, including for the LungVision Imaging and Navigation System (May 2017), the LungVision Tool (May 2018), and the LungVision 2.0 System (May 2019). It has also secured regulatory approval in India (September 2025) and Brazil (July 2025).
Pricing Model
Described as an 'affordable, low-cost solution' with a 'hardware-light design,' LungVision aims to minimize capital costs and offers a lower total cost of ownership compared to alternative solutions like Cone-Beam CT (CBCT), Electromagnetic Navigation Bronchoscopy (ENB), or robotics. Per-procedure costs can be managed with optional disposables, and extended warranty plans are available. A Vizient contract award further facilitates access for customers.
User Experience
LungVision is designed to be easy-to-use, empowering clinicians with real-time, intraoperative imaging for greater precision, confidence, and simplicity. The company continually releases software updates to improve usability, enhance image quality, and refine the pathway planning experience, particularly for peripheral scope navigation.
Support Quality
Body Vision Medical provides comprehensive support, including clinical training and case support after initial purchase. A dedicated clinical education team offers refresher training, education for new staff, and advanced training for experienced users. Extended warranty plans are available to ensure reliable, certified, and expedited support. The company emphasizes high-level customer service backed by in-depth expertise.
Implementation Complexity
The system's 'hardware-light design' and 'small, mobile footprint' contribute to lower implementation complexity. It integrates with standard equipment in the bronchoscopy suite, which helps lower costs and offers flexibility, as it does not require replacement or upgrade of existing C-arm or bronchoscopy setups. A standard chest CT scan (slice thickness <1.5 mm) is required for planning.
Evidence Base
LungVision has demonstrated outstanding results in multicenter clinical trials in the U.S., involving over 400 clinical procedures. Clinical data confirms high diagnostic yields: 89% when used standalone, 91.1% with Ethicon Monarch, and 94.5% with Ion by Intuitive. Studies show diagnostic accuracy of 88.2% at 12 months follow-up. The system has been recognized with awards such as 'Best New Biopsy Solution' (MedTech Breakthrough Awards 2023) and Frost & Sullivan's 2023 North American Technology Innovation Leadership Award. Peer-reviewed publications are also available.
Physician Tip

Consider LungVision for its ability to provide real-time, AI-enhanced 3D imaging during bronchoscopy, which can significantly improve confidence in tool-in-lesion confirmation, especially for small or peripheral nodules. The system's compatibility with existing C-arms and robotic platforms makes it a flexible addition to most bronchoscopy suites. Leverage its low radiation dose and potential for increased diagnostic yield to enhance patient safety and outcomes in lung cancer diagnosis. The integrated planning and virtual bronchoscopy features can aid in complex case navigation.

LungVision is designed for broad compatibility, integrating seamlessly with any conventional 2D C-arm, various navigation platforms (including robotic systems), and standard bronchoscopes. This 'agnostic' approach minimizes the need for significant capital expenditure on new imaging equipment or a complete overhaul of existing bronchoscopy setups. Preoperative CT scans are essential for initial planning, and the system's ability to correct for CT-to-body divergence is a key benefit when integrating with pre-procedural imaging.

Details

Category Oncology AI, Radiology & Imaging AI, Surgical AI
Pricing Contact for pricing
  • Not publicly disclosed; described as an affordable, low-cost solution with lower capital and per-case costs compared to alternatives like cone-beam CT or 3D C-arms
DeploymentOn-premise (integrates with existing C-arm systems, includes main unit and tablet)
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

The LungVision System received FDA clearance (K240943) on October 1, 2024. It is intended to enable users to segment previously acquired 3D CT datasets and overlay and register these 3D segmented data sets with fluoroscopic live X-ray images to support catheter/device navigation during pulmonary procedures.

Integrations
EHR Not specified
Specialties Interventional Radiology, Oncology, Pulmonology

What the Web Says

LungVision, developed by Body Vision Medical, is an AI-powered intraoperative imaging system designed to enhance the accuracy and precision of peripheral lung nodule biopsies. It transforms standard 2D C-arm fluoroscopy images into real-time 3D images, aiming to improve diagnostic yield and facilitate earlier lung cancer detection. Physicians highlight its ability to provide real-time visualization and guidance, even for small and difficult-to-access lesions.

Overall: Positive

Strengths

  • Improved diagnostic yield, with studies reporting overall diagnostic yields of 77.8% to 81.8%, and up to 72.2% for lesions smaller than 20mm.
  • Real-time, intraoperative 3D imaging from standard 2D C-arms, eliminating the need for costly 3D fluoroscopy systems and minimizing CT-to-body divergence.
  • Reduced radiation exposure for both patients and staff compared to traditional 3D systems.
  • Compatibility with all standard biopsy tools, including cryoprobes, and seamless integration with existing bronchoscopy suites and navigation platforms (including robotic systems).
  • Cost-effective solution due to its hardware-light design and ability to integrate with standard equipment.
  • Enhanced confidence for physicians in accurately locating and biopsying peripheral lung nodules, leading to earlier diagnosis and potentially curative approaches.

Limitations

  • Diagnostic yield, while improved, may still be inferior to transthoracic needle aspiration (TTNA) in some cases.
  • Randomized controlled trials are still needed to accurately ascertain its diagnostic yield.
  • Some initial negative biopsy results with LungVision were later found to be positive for malignancy when rebiopsied with TTNA.
  • Potential for pneumothorax as a complication, though reported as infrequent.
  • Requires specific presets for different C-arm models, which might necessitate reprogramming.
  • No specific reviews found on G2, Capterra, or Reddit, which limits insights from those platforms.

Based on reviews from: PMC, Body Vision Medical Website, PR Newswire, YouTube

Last updated: 2026-07-17

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate LungVision

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

PR Newswire
Body Vision Medical Receives Pre-Market Approval for LungVisionu00ae in Singapore, Advancing AI-Powered Imaging for Early Lung Cancer Diagnosis
Body Vision Medical's LungVision advanced imaging platform has received Pre-Market Approval from Singapore's Health Sciences Authority (HSA), enabling full commercialization and aiming to improve early and accurate diagnosis of lung cancer in Singapore.
2025-08
PR Newswire
Body Vision Medical Expands Access to AI Tomou00ae with Major LungVisionu00ae Platform Upgrade
Body Vision Medical has upgraded its LungVision platform to provide universal access to AI Tomo imaging, allowing it to be used with nearly any fluoroscopic C-arm model for real-time visualization of small lesions during bronchoscopy.
2025-08
MedTech Spectrum
Body Vision Medical Secures HSA Approval for AI-Powered LungVision Platform in Singapore
Body Vision Medical has received Pre-Market Approval from Singapore's Health Sciences Authority (HSA) for its LungVision platform, facilitating early lung cancer detection through AI-driven 3D imaging for precise bronchoscopic diagnostics.
2025-08
ParagonCare
Body Vision Medical Receives Regulatory Approval for LungVisionu00ae in Australia, Expanding Access to AI-Driven Advanced Imaging for Lung Cancer Diagnosis
Body Vision Medical's LungVisionu00ae AI-driven advanced imaging system has received regulatory approval from the Therapeutic Goods Administration (TGA) in Australia, expanding access to state-of-the-art AI-driven imaging solutions for lung cancer diagnosis.
2025-03
PR Newswire
Body Vision Medical Receives Regulatory Approval for LungVisionu00ae in India, Expanding Access to AI-Driven Advanced Imaging for Lung Cancer Diagnosis
Body Vision Medical has received regulatory approval from the Central Drugs Standard Control Organization (CDSCO) in India for its LungVision AI-powered advanced imaging system, aiming to improve early and accurate lung cancer diagnosis in the region.
2025-09
Body Vision Medical
Body Vision Medical's Latest LungVisionu00ae Software Enhances AI Tomography, Improves Virtual Bronchoscopy and Introduces Revised Planning Interface
Body Vision Medical announced a software update for its LungVisionu00ae platform (v2.27), which enhances AI Tomou00ae imaging, improves virtual bronchoscopy in peripheral airways, and provides an improved pathway planning experience.
2024-08
Journal of Bronchology & Interventional Pulmonology
Radiation in the Bronchoscopy Suite
A study found that combining LungVision with Cios Spin significantly reduced radiation dose during navigational bronchoscopy procedures compared to using Cios Spin alone, highlighting LungVision's efficacy in dose reduction for real-time 3D imaging.
2025-01
MDPI
Advanced Imaging for Robotic Bronchoscopy: A Review
LungVisionu2122 utilizes augmented fluoroscopy and artificial intelligence to assist with intra-operative nodule localization and generates a navigational pathway by combining preprocedural CT scan images with real-time fluoroscopy.
2023-03

Videos

Product demos, reviews, and walkthroughs for LungVision.

View all on YouTube

Frequently Asked Questions

LungVision utilizes AI to transform images from any 2D C-arm into real-time 3D images, providing augmented fluoroscopic navigation and guidance for endobronchial tools during peripheral lung nodule biopsies. The workflow involves importing a preoperative CT scan for planning, followed by real-time image-guided navigation using AI-powered 3D imaging and augmented fluoroscopy to precisely locate and biopsy lesions.
The LungVision system has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), with the initial system cleared in May 2017, the LungVision Tool in May 2018, and the LungVision 2.0 System in May 2019. While the search results confirm FDA clearances and mention compliance with regulations like good manufacturing practice and medical device reporting, specific details on data privacy and security measures for patient information handled by the AI are not explicitly detailed in the provided snippets.
LungVision offers an affordable, low-cost solution compared to alternatives like cone-beam CT (CBCT) systems or electromagnetic navigation bronchoscopy (ENB), while providing comparable 3D imaging quality and reduced radiation dose. It aims to increase diagnostic yield by correcting for CT-to-body divergence and enabling more precise biopsies of small, peripheral lesions, with reported diagnostic yields approaching 95%.
LungVision is designed to be a pragmatic and affordable investment, minimizing capital costs with a hardware-light design that integrates with existing bronchoscopy suite equipment. While specific pricing figures are not provided, it is noted to be much cheaper than other market alternatives, with optional disposables to manage per-procedure costs and extended warranty service plans available.
While LungVision offers significant advantages, some limitations include the need for randomized controlled trials to accurately ascertain its diagnostic yield. Early studies had small sample sizes and lacked control groups. Additionally, while it can be used with robotic scopes, they are not yet fully integrated, requiring some manual integration.
Yes, LungVision is designed for seamless integration with standard equipment in the bronchoscopy suite, including 2D and 3D C-arms, navigation platforms, bronchoscopes, and biopsy tools. It can augment existing navigational robots with advanced imaging or function as a standalone system.
Body Vision Medical provides clinical training and case support after the initial purchase to ensure confidence and success for users. They aim to ensure optimal performance and long-term value through reliable, certified, and expedited support, including extended warranty service plans.

Related Tools

Surgical Reality Viewer
Surgical Reality
Oncology AI
Surgical Reality offers CE- and FDA-certified AI-powered 3D medical imaging and surgical planning software that transforms CT scans into patient-specific 3D models for thoracic surgery, enhancing precision in complex lung procedures.
Cancer Copilot
Color Health
Oncology AI
Color Health's Cancer Copilot, built with OpenAI, helps oncologists and clinicians identify and order workup needs for recently diagnosed patients, aiming to speed up time to cancer treatment. This AI tool is designed to expand cancer expertise, speed decisions, and improve care, reducing a two-hour clinical task to 10 minutes with over 95% validated accuracy.
Cercare Medical Oncology Virtual Expert
Cercare Medical
Neurology AI
Cercare Medical's Oncology Virtual Expert is an AI-powered brain tumor segmentation module that provides fast, consistent, and semi-automated tumor analysis from standard MRI data, designed for on-premise deployment within existing clinical radiology workflows.
Synapse Lung Nodule AI
Fujifilm Corporation
Oncology AI
Fujifilm's Synapse Lung Nodule AI is an AI software algorithm for detecting pulmonary nodules on CT imaging, aiming to support early detection and treatment of lung cancer.
RadOncAI
Informai (for RadOncAI product) / Global Network for AI in Radiation Oncology (for RadoncAI.net)
Oncology AI
RadOncAI is an AI solution by Informai designed to optimize and enhance radiation oncology workflows, improving efficiency and accuracy in treatment planning and delivery.
FAITH project (Fatigue Therapy – AI-supported Diagnosis and Therapy of Tumour-associated Fatigue Syndrome)
Fimo Health GmbH (Consortium Leader)
Mental & Behavioral Health AI
The FAITH project is developing an AI-based solution for the diagnosis and therapy of tumor-associated fatigue syndrome in cancer patients. It uses wearable sensors, a smartphone app, and artificial intelligence to provide individualized therapy recommendations and monitor mental health.

See all Oncology AI tools →

Suggest an Edit → | Last Verified: 2026-04-17 | First Added: 2026-04-17

Investors who backed LungVision

Funded through the company that built this tool.

AI Tool Finder
AI-powered search. Results may not be comprehensive.